Grufity logoGrufity logo
StocksFundsSearch FilingsAPI

ICU Medical Inc Stock Research

ICUI

116.45USD-0.45(-0.38%)Market Closed
Watchlist

Market Summary

USD116.45-0.45
Market Closed
-0.38%

ICUI Alerts

  • 1 major insider sales recently.
  • Losses in recent quarter

ICUI Stock Price

ICUI RSI Chart

ICUI Valuation

Market Cap

2.8B

Price/Earnings (Trailing)

-57.89

Price/Sales (Trailing)

1.22

EV/EBITDA

25.52

Price/Free Cashflow

-81.62

ICUI Price/Sales (Trailing)

ICUI Profitability

Operating Margin

31.67%

EBT Margin

-2.98%

Return on Equity

-2.19%

Return on Assets

-1.03%

Free Cashflow Yield

-1.23%

ICUI Fundamentals

ICUI Revenue

Revenue (TTM)

2.3B

Revenue Y/Y

-2.08%

Revenue Q/Q

-3.4%

ICUI Earnings

Earnings (TTM)

-48.5M

Earnings Y/Y

-32.91%

Earnings Q/Q

-1.24%

Price Action

52 Week Range

115.33212.43
(Low)(High)

Last 7 days

-9.0%

Last 30 days

-15.6%

Last 90 days

-33.9%

Trailing 12 Months

-23.4%

ICUI Financial Health

Current Ratio

2.62

ICUI Investor Care

Shares Dilution (1Y)

0.87%

Diluted EPS (TTM)

-2.01

Historical Charts for Stock Metrics

Get all data in R, Python etc through our Historical Stock Data APIs
Net sales

Latest Insider Trading transactions for ICUI

Filter Transactions
Datesorted ascendingNameBuy/Sell$ ValueAvg. Price# SharesTitle
2023-09-08
Voigtlander Christian B.
sold
-883,930
129
-6,850
chief operating officer
2023-07-12
Jain Vivek
sold
-5,400,720
180
-30,000
chairman and ceo
2023-07-12
Jain Vivek
acquired
1,763,700
58.79
30,000
chairman and ceo
2023-06-14
Jain Vivek
sold
-5,660,090
188
-30,000
chairman and ceo
2023-06-14
Jain Vivek
acquired
1,763,700
58.79
30,000
chairman and ceo
2023-06-07
FINNEY ELISHA W
sold
-36,939
190
-194
-
2023-06-02
Jain Vivek
gifted
-
-
-85.00
chairman and ceo
2023-05-17
Greenberg David C.
acquired
-
-
485
-
2023-05-17
Abbey Donald
acquired
-
-
485
-
2023-05-17
Hoffmeister David F
acquired
-
-
485
-

1–10 of 50

Which funds bought or sold ICUI recently?

View All Details
Datesorted ascendingFund NameType% Chg$ Change$ Held% Portfolio
2023-09-20
BARCLAYS PLC
reduced
-18.07
-1,276,000
9,814,000
0.01%
2023-09-18
WASHINGTON CAPITAL MANAGEMENT, INC
unchanged
-
38,367
516,751
0.44%
2023-09-12
Farther Finance Advisors, LLC
new
-
535
535
-%
2023-09-08
TUCKER ASSET MANAGEMENT LLC
unchanged
-
543
7,306
-%
2023-08-23
WOLVERINE TRADING, LLC
new
-
832,066
832,066
-%
2023-08-22
VIRGINIA RETIREMENT SYSTEMS ET AL
new
-
534,570
534,570
-%
2023-08-21
CALIFORNIA STATE TEACHERS RETIREMENT SYSTEM
reduced
-2.65
216,683
4,415,900
0.01%
2023-08-21
OSAIC HOLDINGS, INC.
added
8.93
26,641
180,251
-%
2023-08-21
TEACHERS RETIREMENT SYSTEM OF THE STATE OF KENTUCKY
added
10.87
99,000
598,000
0.01%
2023-08-21
BOKF, NA
reduced
-38.34
-20,546
40,984
-%

1–10 of 46

Latest Funds Activity

Are funds buying ICUI calls or puts?
Calls
Puts
No. of funds holding Calls - Puts
Net Call Options
No. of funds that own ICUI
No. of Funds

Schedule 13G FIlings of ICU Medical

Date FiledName of FilerPercent of ClassNo. of SharesForm Type
Feb 14, 2023
t. rowe price investment management, inc.
10.1%
2,423,228
SC 13G/A
Feb 10, 2023
janus henderson group plc
10.7%
2,557,226
SC 13G/A
Feb 09, 2023
vanguard group inc
8.77%
2,104,172
SC 13G/A
Feb 06, 2023
wellington management group llp
9.87%
2,366,386
SC 13G
Jan 31, 2023
blackrock inc.
7.5%
1,787,807
SC 13G/A
Feb 14, 2022
price t rowe associates inc /md/
12.8%
2,725,540
SC 13G/A
Feb 10, 2022
vanguard group inc
9.18%
1,950,253
SC 13G/A
Feb 10, 2022
janus henderson group plc
10.8%
2,294,880
SC 13G/A
Feb 01, 2022
blackrock inc.
7.9%
1,686,855
SC 13G/A
Jan 12, 2022
smiths group international holdings ltd
10.5%
2,500,000
SC 13D

Recent SEC filings of ICU Medical

View All Filings
Date Filed Form Type Document
Sep 11, 2023
4
Insider Trading
Sep 08, 2023
144
Notice of Insider Sale Intent
Aug 07, 2023
8-K
Current Report
Aug 07, 2023
10-Q
Quarterly Report
Jul 14, 2023
4
Insider Trading
Jul 12, 2023
144
Notice of Insider Sale Intent
Jun 15, 2023
4
Insider Trading
Jun 14, 2023
144
Notice of Insider Sale Intent

ICUI Fair Value

Loading...

Peers (Alternatives to ICU Medical)

View All Peers In Detail
NameMkt Capsorted ascendingRevenuePrice %, 1MReturns, 1YP/EP/SRev 1-YrInc 1-Yr
LARGE-CAP
108.3B
19.5B
3.38% 36.58%
39.99
5.57
10.36% 30.30%
101.2B
6.7B
-0.75% 50.83%
71.05
15.19
11.75% -0.66%
77.5B
13.4B
6.45% 36.39%
85
5.78
8.69% 3.17%
71.3B
19.0B
-4.29% 12.66%
44.09
3.79
0.46% -5.24%
42.3B
5.7B
-8.22% -17.24%
30.48
7.49
5.64% -4.53%
MID-CAP
9.5B
937.8M
-2.12% 37.22%
325.65
10.11
16.30% 250.21%
7.1B
616.6M
-12.54% -24.86%
29.24
11.56
69.52% 343.68%
5.1B
1.1B
-6.10% -12.07%
24.23
4.65
12.63% 50.85%
2.6B
452.1M
-21.20% -33.94%
-26.32
5.78
24.99% 24.09%
1.3B
790.3M
-27.09% -56.49%
-5.97
1.69
3.21% -1604.53%
SMALL-CAP
1.6B
421.8M
-15.15% 56.11%
-9.32
3.69
44.49% -2.43%
947.4M
780.7M
-7.75% -9.65%
-26.32
1.21
4.68% -510.17%
839.3M
239.8M
0.70% 0.15%
-22.16
3.5
-4.74% -31.15%
609.7M
162.9M
-27.67% -61.65%
-11.53
3.74
42.67% 12.82%

ICU Medical News

MarketBeat
State Board of Administration of Florida Retirement System Trims ....
MarketBeat,
4 days ago
Zacks Investment Research

Returns for ICUI

Cumulative Returns on ICUI

5.5%


10-Year Cumulative Returns

-1.2%


7-Year Cumulative Returns

-15.2%


5-Year Cumulative Returns

-15.0%


3-Year Cumulative Returns

Risks for ICUI

What is the probability of a big loss on ICUI?

78.1%


Probability that ICU Medical stock will be more than 20% underwater in next one year

53.1%


Probability that ICU Medical stock will be more than 30% underwater in next one year.

29.6%


Probability that ICU Medical stock will be more than 40% underwater in next one year.
*Calculated based on probability distribution of losses observed in actual data in the last 5 years.

How does ICUI drawdown profile look like?

Y-axis is the maximum loss one would have experienced if ICU Medical was unfortunately bought at previous high price.

Drawdowns

Financials for ICU Medical

Income Statement (Last 12 Months)
(In Millions)
Income Statement (Last 12 Months)
(In Millions)
(*) denotes actual numbers (not divided by Millions)
Description(%) Q/Q2023Q22023Q12022Q42022Q32022Q22022Q12021Q42021Q32021Q22021Q12020Q42020Q32020Q22020Q12019Q42019Q32019Q22019Q12018Q42018Q32018Q2
Revenue-0.5%2,2942,3062,2802,0431,7811,5411,3161,2961,2791,2601,2711,2661,2551,2641,2661,2911,3111,3591,4001,4301,446
Gross Profit3.4%746721698650592548491484470453461456460458472492508556570573550
Operating Expenses3.1%734712741669572493368357356354363367364355365412459501540491474
  S&GA Expenses-1.3%600608608547468383303295291284284281276277277283294308320319319
  R&D Expenses-0.3%89.0089.0093.0083.0072.0061.0047.0046.0044.0043.0043.0044.0046.0047.0049.0050.0051.0053.0053.0053.0053.00
EBITDA-100.0%-112-130151159221219207193185174178181192159-----
EBITDA Margin-100.0%-0.05*-0.06*0.08*0.10*0.17*0.17*0.16*0.15*0.15*0.14*0.14*0.14*0.15*0.12*-----
Interest Expenses14.9%-49.66-58.34-66.3751.0030.0015.002.001.001.002.002.002.001.001.001.001.001.001.001.001.001.00
Earnings Before Taxes-11.7%-76.75-68.73--123-44.9724.00-13011810497.0088.0095.0010211581.0050.0052.0022.0075.0078.00
EBT Margin100.0%--0.03*--0.06*-0.03*0.02*0.10*0.10*0.09*0.08*0.08*0.07*0.08*0.08*0.09*0.06*-----
Net Income-5.3%-48.49-46.03-74.29-38.835.0041.0010310910394.0087.0081.0083.0087.0010173.0047.0055.0029.0086.0086.00
Net Income Margin100.0%--0.02*-0.03*-0.02*0.00*0.03*0.08*0.08*0.08*0.07*0.07*0.06*0.07*0.07*0.08*------
Free Cashflow100.0%--100-152-68.5912.0013719918717715413110781.0068.005.00------
Balance Sheet
(In Millions)
Balance Sheet
(In Millions)
(*) denotes actual numbers (not divided by Millions)
Description(%) Q/Q2023Q22023Q12022Q42022Q32022Q22022Q12021Q42021Q32021Q22021Q12020Q42020Q32020Q22020Q12019Q42019Q32019Q22019Q12018Q42018Q32018Q2
Assets-0.2%4,4634,4714,5164,4504,5904,7471,8811,8391,8031,7651,7641,7301,8591,8171,6921,6381,6231,6131,5851,5451,526
  Current Assets2.6%1,2451,2131,2351,1991,1901,1741,0301,0119739289219001,0371,002882944930921927913900
    Cash Equivalents-11.3%196221209244256329553519462424396351446420269316292296345319309
  Inventory3.7%775748696625583536290292300300315322323312338344330322311292289
  Net PPE-1.2%617624636656668674468458459459467456455456456444437433433425416
  Goodwill0.1%1,4641,4631,4491,3701,4211,52743.0033.0033.0033.0033.0033.0032.0031.0031.0011.0011.0011.0011.0013.0013.00
  Current Liabilities4.7%484462495489486494201185184180195185359357248255260238249203202
    LT Debt, Current15.1%40.0035.0030.0024.0019.0014.00------150150-------
    LT Debt, Non Current-0.7%1,6011,6121,6241,6301,6361,642---------------
Shareholder's Equity0.7%2,1152,1002,0902,0132,0862,1791,6161,5901,5571,5211,5021,4521,4121,3761,3771,3401,3181,2831,2641,2601,257
  Retained Earnings-1.2%818828838853866874912892861832809783758739722701675652621628628
  Additional Paid-In Capital0.4%1,3451,3401,3311,3231,3101,306721711706702693683675666669660658660658652644
Shares Outstanding0.2%24.0024.0024.0024.0024.0024.0021.0021.0021.0021.0021.0021.0021.0021.0021.0021.0021.0021.0020.0020.0020.00
Cashflow (Last 12 Months)
(In Millions)
Cashflow (Last 12 Months)
(In Millions)
(*) denotes actual numbers (not divided by Millions)
Description(%) Q/Q2023Q22023Q12022Q42022Q32022Q22022Q12021Q42021Q32021Q22021Q12020Q42020Q32020Q22020Q12019Q42019Q32019Q22019Q12018Q42018Q32018Q2
Cashflow From Operations306.6%40.00-19.54-62.1322.0099.00215268263260235223193168162102103104160160195242
  Share Based Compensation6.1%35.0033.0036.0037.0034.0033.0027.0025.0024.0023.0024.0024.0022.0023.0022.0022.0025.0025.0024.0024.0022.00
Cashflow From Investing-21.8%-69.31-56.90-1,909-1,918-1,926-1,939-90.69-98.65-101-93.55-98.14-158-158-179-166-84.97-106-98.86-103-113-119
Cashflow From Financing-6.7%-29.59-27.721,6371,6321,6311,635-16.873.00-146-141-0.04-1.13148145-10.91-14.31-13.37-7.038.00-54.98-45.81
  Buy Backs---11.00---8.00---13.00---19.00---6.00-6.00

ICUI Income Statement

2023-06-30
Condensed Consolidated Statements of Income - USD ($)
shares in Thousands, $ in Thousands
3 Months Ended6 Months Ended
Jun. 30, 2023
Jun. 30, 2022
Jun. 30, 2023
Jun. 30, 2022
REVENUES:    
Revenue from Contract with Customer, Excluding Assessed Tax$ 549,310$ 561,004$ 1,117,959$ 1,104,126
Cost of goods sold356,983393,411733,591767,706
Gross Profit192,327167,593384,368336,420
OPERATING EXPENSES:    
Selling, general and administrative150,895158,748303,467311,960
Research and development22,30222,56242,06346,433
Restructuring, strategic transaction and integration12,35413,52523,36747,430
Change in fair value of contingent earn-out4,016(27,194)3,316(27,194)
TOTAL OPERATING EXPENSES189,567167,641372,213378,629
(LOSS) INCOME FROM OPERATIONS2,760(48)12,155(42,209)
Interest Expense(24,121)(15,440)(46,636)(28,495)
OTHER (EXPENSE) INCOME, net(1,502)(1,366)(1,771)(951)
(Loss) Income from Continuing Operations before Income Taxes, Noncontrolling Interest(22,863)(16,854)(36,252)(71,655)
BENEFIT (PROVISION) FOR INCOME TAXES12,9299,38016,50626,113
NET (LOSS) INCOME$ (9,934)$ (7,474)$ (19,746)$ (45,542)
NET INCOME PER SHARE    
Basic (in dollars per share)$ (0.41)$ (0.31)$ (0.82)$ (1.91)
Diluted (in dollars per share)$ (0.41)$ (0.31)$ (0.82)$ (1.91)
WEIGHTED AVERAGE NUMBER OF SHARES    
Basic (in shares)24,07523,89724,04523,787
Diluted (in shares)24,07523,89724,04523,787

ICUI Balance Sheet

2023-06-30
Condensed Consolidated Balance Sheets - USD ($)
$ in Thousands
Jun. 30, 2023
Dec. 31, 2022
CURRENT ASSETS:  
Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents$ 195,887$ 208,784[1]
Short-term investment securities1,8124,224[1]
TOTAL CASH, CASH EQUIVALENTS AND INVESTMENT SECURITIES197,699213,008[1]
Accounts receivable, net of allowance for doubtful accounts162,225221,719[1]
Inventories775,269696,009[1]
Prepaid income taxes13,76615,528[1]
Prepaid expenses and other current assets95,78388,932[1]
TOTAL CURRENT ASSETS1,244,7421,235,196[1]
PROPERTY AND EQUIPMENT, net616,540636,113[1]
Operating Lease, Right-of-Use Asset76,02874,864[1]
Long-term investment securities0516
GOODWILL1,464,4781,449,258[1]
INTANGIBLE ASSETS, net929,830982,766[1]
Deferred Income Tax Assets31,46631,466
OTHER ASSETS99,960105,462[1]
TOTAL ASSETS4,463,0444,515,641[1]
CURRENT LIABILITIES:  
Accounts payable167,054215,902[1]
Accrued liabilities254,508242,769[1]
Long-term Debt, Current Maturities40,37529,688
Income tax liability19,9546,200[1]
Contingent earn-out liability1,9890
TOTAL CURRENT LIABILITIES483,880494,559[1]
Contingent Earn-Out Liability, Noncurrent26,94425,572[1]
Long-term Debt, Excluding Current Maturities1,600,7201,623,675
Other long-term liabilities109,858114,104
DEFERRED INCOME TAXES89,684126,007[1]
INCOME TAX LIABILITY37,14041,796[1]
COMMITMENTS AND CONTINGENCIES00[1]
STOCKHOLDERS' EQUITY:  
Convertible preferred stock, $1.00 par value Authorized-500 shares; Issued and outstanding - none00[1]
Common stock, $0.10 par value - Authorized-80,000 shares2,4112,399[1]
Additional paid-in capital1,345,0571,331,249[1]
Treasury Stock, at cost(1,611)(243)[1]
Retained earnings817,755837,501[1]
Accumulated other comprehensive loss(48,794)(80,978)[1]
TOTAL STOCKHOLDERS' EQUITY2,114,8182,089,928[1]
TOTAL LIABILITIES AND STOCKHOLDERS' EQUITY$ 4,463,044$ 4,515,641[1]
[1]December 31, 2022 balances were derived from audited consolidated financial statements.
Vivek Jain
8500
ICU Medical, Inc., together with its subsidiaries, develops, manufactures, and sells medical devices used in infusion therapy and critical care applications worldwide. The company's infusion therapy products include needlefree products under the MicroClave, MicroClave Clear, and NanoClave brands; Neutron catheter patency devices; SwabCap and SwabTip disinfecting caps; Tego hemodialysis connectors; ClearGuard HD, an antimicrobial barrier cap for hemodialysis catheters; and ChemoClave and ChemoLock closed system transfer devices, as well as Diana hazardous drug compounding system for the preparation of hazardous drugs. It also provides IV therapy and diluents, such as sodium chloride, dextrose, balanced electrolyte solutions, lactated ringer's, ringer's, mannitol, sodium chloride/dextrose, and sterile water; and irrigation comprising sodium chloride and sterile water irrigation, physiologic solutions, ringer's irrigation, acetic acid irrigation, glycine irrigation, sorbitol-mannitol irrigation, flexible containers, and pour bottle options. The company offers infusion pumps under the Plum 360 and LifeCare PCA brands; IV mediation safety software, including ICU Medical MedNet, an enterprise-class medication management platform that connects smart pumps to hospital's electronic health records, asset tracking systems, and alarm notification platforms; and related professional services. It also provides critical care products, such as Cogent 2-in-1 and CardioFlo hemodynamic monitoring systems; TDQ and OptiQ cardiac output monitoring catheters; TriOx venous oximetry catheters; Transpac blood pressure transducers; and SafeSet closed blood sampling and conservation systems. The company sells its products to acute care hospitals, wholesalers, ambulatory clinics, and alternate site facilities, including outpatient clinics, home health care providers, and long-term care facilities. ICU Medical, Inc. was founded in 1984 and is headquartered in San Clemente, California.